Automated & Closed-Cell Therapy Processing Systems Market Size and Share 2032

Automated and Closed Cell Therapy Processing Systems market size was valued at USD 1,201.39 million in 2024 and is projected to reach USD 6,293.97 million by 2032.

By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa); By End-User (Hospitals, Research Institutions, Biotechnology Companies, Pharmaceutical Companies); By Technology (Automation Technology, Gene-Editing Technology, Stem-Cell Processing Technology); By Product Type (Automated Cell Therapy Processing Systems, Closed Cell Therapy Processing Systems)

SKU: CR3786Report Pages: 250Category: HealthcareReport Format: PDF, ExcelLast Updated: Mar 13Author: Shweta BishtReviewed by: Deepti AgrawalPreferred on

Market Report Metrics

Revenue, 2024 -
USD 1,201.39 million
Forecast Year -
2032
CAGR (2024–2032)
23%
Report Coverage
Global
REPORT ATTRIBUTE DETAILS
Historical Period  2020-2023
Base Year  2024
Forecast Period  2025-2032
Automated And Closed Cell Therapy Processing Systems Market Size 2024  USD 1,201.39 Million
Automated And Closed Cell Therapy Processing Systems Market, CAGR  23%
Automated And Closed Cell Therapy Processing Systems Market Size 2032  USD 6,293.97 Million

Market Overview

The Automated And Closed Cell Therapy Processing Systems Market is projected to grow from USD 1,201.39 million in 2024 to an estimated USD 6,293.97 million by 2032, with a compound annual growth rate (CAGR) of 23% from 2024 to 2032.

Key drivers of the automated and closed cell therapy processing systems market include advancements in cell-based therapies, rising demand for personalized medicine, and the increasing adoption of automation in manufacturing processes. The growing number of clinical trials and the increasing prevalence of chronic diseases are fueling the need for efficient and scalable manufacturing solutions for cell therapies. Furthermore, the shift towards closed systems ensures higher levels of safety and minimizes the risk of contamination, which is crucial for the production of these sensitive biological products.

Regionally, North America is leading the market due to the presence of advanced healthcare infrastructure, a strong focus on research and development, and significant investments in biotechnology and pharmaceutical industries. Europe follows closely, with increasing government support and funding for biotechnology and cell therapy innovations. In Asia Pacific, countries like China, Japan, and India are expected to see substantial market growth due to rising healthcare expenditures, expanding healthcare infrastructure, and growing biopharmaceutical sectors. The Latin America and Middle East & Africa regions are gradually embracing automated and closed cell therapy processing systems as the demand for biopharmaceutical products and advanced healthcare technologies continues to rise.

Market Insights:

  • The Automated and Closed Cell Therapy Processing Systems Market is projected to grow from USD 1,201.39 million in 2024 to an estimated USD 6,293 million by 2032, with a CAGR of 23%.
  • Rising demand for personalized medicine and cell-based therapies is driving the adoption of automated and closed processing systems.
  • Automation in production processes and the use of closed systems are enhancing safety and reducing the risk of contamination in cell therapy manufacturing.
  • Stringent regulatory requirements and the high cost of advanced processing systems may limit market growth in some regions.
  • North America is the dominant region due to strong healthcare infrastructure, extensive R&D investments, and a focus on biotechnology innovation.
  • The Asia-Pacific region is witnessing rapid growth, fueled by increased healthcare spending, expanding biopharmaceutical sectors, and government support.
  • Latin America, the Middle East, and Africa are gradually adopting automated and closed cell therapy processing systems as part of their long-term healthcare development strategies.

Market Drivers:

Rising Demand for Personalized Medicine:

The increasing demand for personalized medicine has been a critical driver in the adoption of automated and closed cell therapy processing systems. Personalized treatments, designed to target specific genetic and molecular profiles, require efficient, scalable, and safe production systems. For instance, as of 2022, more than 100,000 clinical trials were ongoing worldwide, targeting personalized treatments for diseases like cancer, diabetes, and genetic disorders. The U.S. National Institutes of Health (NIH) allocated over $100 million in 2023 to support the development of advanced manufacturing technologies for cell therapies. This funding encourages the creation of automated systems to ensure high-quality, scalable production to meet the demand for personalized treatments.

Technological Advancements in Cell Therapy Manufacturing:

Technological innovations are essential for driving the adoption of automated and closed cell therapy processing systems. Automation ensures efficiency, safety, and scalability in manufacturing, which are crucial for meeting the rising demand for cell therapies. For instance, in 2021, Thermo Fisher Scientific launched an automated platform for the large-scale production of cell and gene therapies, a move that was supported by a $300 million investment in R&D, specifically targeting advancements in gene therapy manufacturing. According to the U.S. Department of Energy, over $300 million has been allocated to research and development in advanced cell manufacturing technologies, with a focus on automation to streamline production. These investments reflect a growing recognition of the need for automation to enhance the efficiency, scalability, and safety of cell-based therapies.

Government Initiatives and Regulatory Support:

Government support is a major driver for the growth of automated and closed cell therapy processing systems. Regulatory frameworks and financial incentives play a key role in advancing the development and manufacturing of cell therapies. For instance, the European Union's Horizon 2020 program, which funded more than €8 billion in health-related research between 2014 and 2020, supported numerous projects focused on advanced cell therapy production systems. The U.S. Food and Drug Administration (FDA) has also been actively involved in the regulation and approval of cell therapies, issuing over 25 approvals for cell-based treatments in the past five years. These initiatives ensure that companies receive the regulatory clarity and financial support necessary to scale up cell therapy manufacturing, accelerating the growth of the automated processing systems market.

Increase in Chronic Diseases and Aging Populations:

The global increase in chronic diseases and aging populations has fueled the demand for cell-based therapies, driving the need for more advanced manufacturing systems. The World Bank forecasts that by 2050, the global population aged 65 and older will double to 1.5 billion, which will lead to a higher incidence of age-related diseases such as Alzheimer's, cardiovascular conditions, and osteoarthritis. In response, governments and healthcare organizations are investing in novel treatments, including cell therapies. For instance, the National Institutes of Health (NIH) has committed over $100 billion in research funding over the next decade to combat chronic diseases. As the patient population grows, the need for efficient, automated systems to scale production of cell therapies becomes even more critical. Companies like Novartis and Gilead Sciences are expanding their research and investment into automated platforms to meet the increasing demand for gene therapies and cell-based immunotherapies, particularly in the treatment of chronic and age-related diseases.

Shift Toward Automation and Digitization:

One of the prominent trends in the automated and closed cell therapy processing systems market is the increasing shift toward automation and digitization. Biopharmaceutical companies are increasingly adopting automated solutions to improve the efficiency and reproducibility of cell therapy production. Automation helps to reduce human error, ensures higher throughput, and minimizes contamination risks. For instance, the U.S. National Institutes of Health (NIH) has awarded over $50 million in grants since 2022 to research projects focused on the integration of automation into cell manufacturing systems. This trend toward automation is supported by innovations such as robotic arms, digital control systems, and AI-based solutions that enable more precise control over manufacturing processes. Automation is expected to play a key role in reducing production costs while meeting the growing demand for cell-based therapies.

Increase in Regulatory Focus and Standardization:

Another key trend is the growing emphasis on regulatory standards and the push for standardized processes in cell therapy manufacturing. As the number of cell therapies in clinical trials and on the market grows, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are tightening their regulations to ensure the safety and quality of these therapies. For instance, the FDA has been actively working on a set of guidelines for regenerative medicine since 2019, which has significantly influenced how companies approach the production of cell therapies. In 2022, the FDA released new guidance on cell therapy manufacturing that requires the use of closed systems to reduce contamination risks. These regulatory efforts are encouraging companies to adopt advanced automated systems that comply with stringent safety and quality standards.

Focus on Scalable and Cost-Effective Solutions:

As the demand for cell therapies increases, there is a growing focus on scalable and cost-effective production solutions. The manufacturing of cell-based therapies often involves complex, labor-intensive processes that can be expensive. To address these challenges, companies and research organizations are developing automated systems that can scale production without significantly increasing costs. For instance, The U.S. Department of Energy (DOE) has dedicated over $200 million in funding since 2021 to support projects focused on reducing the costs associated with cell therapy production and improving scalability. This includes investments in technology that can streamline processes, reduce labor requirements, and lower the overall cost of manufacturing cell therapies. Companies like Lonza Group have been at the forefront of these innovations, focusing on developing scalable systems that meet market demands.

Collaborations Between Industry and Academia:

Collaborations between industry leaders and academic institutions are becoming more common in the automated and closed cell therapy processing systems market. These partnerships are focused on accelerating the development and commercialization of advanced manufacturing technologies. For instance, the European Union’s Horizon 2020 program has funded numerous research initiatives aimed at developing innovative manufacturing systems for cell therapies. The program allocated over €1 billion to biopharmaceutical research in 2020 alone, with a significant portion directed toward projects involving automation in cell therapy production. Companies like Thermo Fisher Scientific and Roche are also collaborating with academic institutions to explore new approaches to scaling up and automating the production of cell therapies, ensuring that these systems are both cutting-edge and compliant with global regulatory standards. These trends reflect the evolving landscape of automated and closed cell therapy processing systems, highlighting the increasing emphasis on efficiency, safety, and scalability in the industry. The collaboration between governments, regulatory bodies, and industry leaders will continue to shape the future of this market.

Market Challenges Analysis:

High Costs and Complex Manufacturing Requirements:

One of the significant challenges facing the automated and closed-cell therapy processing systems market is the high costs associated with manufacturing these advanced systems. Developing and scaling up cell therapies requires specialized equipment, expertise, and high-quality materials, all of which contribute to the overall production costs. Automated systems that ensure safety, scalability, and efficiency come with substantial capital investments, which can be a barrier for smaller companies or startups attempting to enter the market. Moreover, as the production of cell therapies is highly specialized, the manufacturing process itself is complex, requiring ongoing investments in research and development to enhance system performance and compliance with evolving regulatory requirements. For instance, companies that manufacture closed cell therapy processing systems, such as Lonza Group, often face challenges in balancing cost control with the need for innovation. These systems require significant investment in technology, software, and infrastructure to support scalable production. While large companies can absorb these costs, smaller players in the market may struggle to remain competitive due to the substantial initial and ongoing investments required. As the cell therapy market grows, the pressure to lower production costs will continue to increase, pushing manufacturers to seek cost-effective solutions while maintaining high standards of quality and compliance. In response to this challenge, research organizations and governments are investing in funding programs to support cost-effective innovations in cell therapy manufacturing, but this remains an ongoing challenge.

Regulatory and Compliance Hurdles:

Another key challenge is the complex and evolving regulatory landscape surrounding cell therapy manufacturing, which can delay market entry and increase the overall cost of production. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional health authorities have stringent requirements for the approval of new therapies. These regulations ensure that cell therapies are safe and effective, but they also impose significant challenges on manufacturers, particularly in the context of new and emerging technologies. The adoption of automated and closed systems for manufacturing is subject to continuous scrutiny from these agencies, requiring constant adjustments to meet safety standards and obtain the necessary certifications for clinical and commercial production. For instance, the FDA has been actively involved in issuing new guidelines for regenerative medicine, including cell therapies. In 2022, the FDA updated its guidelines for gene and cell therapy products, which highlighted the need for manufacturers to adopt closed-system technology to minimize contamination risks. While these regulatory updates ensure the safety and effectiveness of therapies, they also impose additional costs and time delays for companies trying to comply with these ever-changing standards. The need to adapt to different regulatory environments while maintaining consistency and quality in manufacturing systems is a persistent challenge for the industry, impacting the speed of innovation and the accessibility of advanced cell therapies.

Market Opportunities:

The growing demand for regenerative medicine presents a significant opportunity for automated and closed cell therapy processing systems. As chronic diseases, age-related conditions, and genetic disorders become more prevalent, there is an increasing need for advanced therapies that can repair, replace, or regenerate damaged tissues and organs. Cell-based therapies, particularly those involving stem cells and gene therapies, are at the forefront of this medical revolution. The ability to produce these therapies at scale, while maintaining high quality and safety, relies heavily on the use of automated systems that can manage complex, high-volume production processes. As governments and healthcare providers invest more in regenerative medicine, companies specializing in cell therapy processing systems stand to benefit from the growing demand for reliable, scalable, and cost-effective manufacturing solutions. For instance, the U.S. National Institutes of Health (NIH) has allocated substantial funding toward advancing regenerative medicine, which directly supports the adoption of automated manufacturing systems for cell-based treatments.

Emerging markets offer significant growth opportunities for automated and closed cell therapy processing systems, driven by increasing healthcare investments and supportive government policies. As populations in regions like Asia-Pacific, Latin America, and the Middle East grow, healthcare infrastructures are evolving to address the rising burden of chronic diseases and an aging population. Governments in these regions are increasingly recognizing the potential of cell therapies and are investing in the development of advanced biomanufacturing technologies. For example, the World Bank has been supporting healthcare advancements in low and middle-income countries by providing financial resources for the development of cutting-edge technologies, including automated systems for cell therapy production. These initiatives create a fertile environment for market expansion, as local manufacturers look to integrate advanced, scalable solutions to meet the needs of their growing patient populations.

Market Segmentation Analysis:

By Type

In terms of type, the market is primarily divided into two categories: automated and closed cell therapy processing systems. Automated systems are designed to streamline and optimize the production process by reducing manual intervention, thus enhancing efficiency, scalability, and reproducibility. These systems are particularly suited for large-scale production, where speed and consistency are crucial. Closed cell therapy systems, on the other hand, are designed to minimize the risk of contamination during production by providing a sealed, controlled environment for cell processing. Closed systems are becoming increasingly popular due to their ability to maintain sterility and reduce contamination risks, ensuring the safety of the final product.

By Technology

The market is also segmented by technology, including automation technology, gene-editing technology, and stem-cell processing technology. Automation technology is a significant driver, with advancements in robotics, AI, and machine learning allowing for improved control, higher throughput, and reduced human error in cell therapy production. Gene-editing technologies, such as CRISPR, enable precise modifications to cells for therapeutic purposes, and they require specialized systems to maintain optimal conditions for gene editing and cell cultivation. Stem-cell processing technology is another critical area, with systems designed to isolate, expand, and differentiate stem cells for use in regenerative medicine.

By End-User

The end-user segmentation includes hospitals, research institutions, biotechnology companies, and pharmaceutical companies. Hospitals are increasingly adopting cell therapies to treat a wide range of conditions, from cancers to autoimmune disorders, leading to a growing demand for efficient processing systems. Research institutions play a significant role in developing new cell therapies and are major users of automated and closed systems for clinical trials and basic research. Biotechnology companies are involved in the development and production of cell-based therapies, making them significant consumers of processing systems to scale production. Pharmaceutical companies, which are heavily involved in the commercialization of cell therapies, rely on these systems to meet the production demands of large-scale therapy distribution.

Segmentations:

Based on Product Type:

  • Automated Cell Therapy Processing Systems
  • Closed Cell Therapy Processing Systems

Based on Technology:

  • Automation Technology
  • Gene-Editing Technology
  • Stem-Cell Processing Technology

Based on End-User:

  • Hospitals
  • Research Institutions
  • Biotechnology Companies
  • Pharmaceutical Companies

Based on Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Regional Analysis:

North America

North America is the leading region in the automated and closed cell therapy processing systems market, accounting for a substantial market share. The United States is the dominant player in this region, contributing to over 60% of the market share. This growth is driven by the country’s advanced healthcare infrastructure, substantial research and development (R&D) investments, and regulatory support. The U.S. Food and Drug Administration (FDA) plays a pivotal role in shaping the market by providing clear regulatory guidelines for cell therapy production, which has bolstered the adoption of automated and closed cell processing systems. Moreover, the presence of leading companies, such as Thermo Fisher Scientific, Lonza Group, and Gilead Sciences, further strengthens the market in North America. The U.S. also leads in the number of clinical trials and approvals for cell-based therapies.

Europe

Europe holds a significant share of the automated and closed cell therapy processing systems market, contributing around 25% to the global market. Key players in the region include Germany, the United Kingdom, and France, with Germany being the largest market in Europe. The region benefits from strong government initiatives, such as the European Medicines Agency’s (EMA) efforts to regulate and promote cell therapy production through its “Advanced Therapy Medicinal Products (ATMPs)” framework. The growing demand for personalized medicine in Europe is another factor driving the adoption of automated systems. The European Union's focus on creating a unified regulatory framework has made it easier for companies to scale their operations across member countries, promoting market growth.

Asia-Pacific

The Asia-Pacific region is emerging as one of the fastest-growing markets for automated and closed cell therapy processing systems, contributing to around 10-12% of the global market share. The rapid expansion of healthcare infrastructure, increasing prevalence of chronic diseases, and growing investments in biotechnology and healthcare R&D are major factors driving this growth. Countries such as China, Japan, and India are leading the charge, with China having a particularly strong position due to its booming biopharmaceutical industry and government-backed initiatives aimed at advancing medical technologies.

Key Player Analysis:

  • Miltenyi Biotec
  • Lonza
  • Fresenius Kabi AG
  • Danaher Corporation
  • BioSpherix, LLC
  • Terumo Corporation
  • Sartorius AG
  • ThermoGenesis Holdings, Inc.
  • CELLARS
  • Thermo Fisher Scientific Inc.

Competitive Analysis:

The competitive landscape of the Automated and Closed Cell Therapy Processing Systems market is characterized by a mix of established players and emerging companies, all vying for market share through innovation, technological advancements, and strategic partnerships. Leading global players such as Thermo Fisher Scientific, Lonza Group, and Merck are at the forefront, offering comprehensive solutions that span automated and closed cell processing systems. These companies leverage their robust R&D capabilities, extensive distribution networks, and established relationships with biopharmaceutical and biotechnology firms to maintain dominance in the market. Moreover, the increasing demand for scalable, high-quality manufacturing systems has led to collaborations between industry leaders and academic institutions, fostering the development of next-generation technologies. Smaller players and startups are also emerging, focusing on niche applications and providing specialized solutions that cater to specific aspects of cell therapy production, such as gene-editing or stem-cell processing. The market is highly competitive due to the constant need for innovation, cost reduction, and adherence to stringent regulatory standards, especially regarding safety and contamination control. Furthermore, government support and funding, particularly in North America, Europe, and Asia-Pacific, are fueling the growth of biopharmaceutical industries, creating additional competitive pressure. As the market continues to grow, players are focusing on enhancing their product portfolios, expanding into emerging markets, and adopting advanced technologies like AI and automation to meet the evolving needs of cell therapy manufacturing. Competitive differentiation is largely driven by technological capabilities, regulatory compliance, and the ability to scale production efficiently.

Recent Developments:

  1. In September 2024, Vertex Pharmaceuticals Incorporated signed a long-term commercial supply agreement with Lonza to produce Casgevy, a CRISPR/Cas9 gene-edited cell therapy for treating sickle cell disease and β-thalassemia.
  2. In December 2023, Miltenyi Biotec and Replay entered into a licensing and manufacturing agreement to develop GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapies targeting PRAME, a tumor-associated neoantigen.

Market Concentration & Characteristics:

The automated and closed cell therapy processing systems market exhibits moderate to high concentration, dominated by a few large players with established capabilities in biotechnology, biopharmaceuticals, and cell therapy manufacturing. Key industry leaders such as Thermo Fisher Scientific, Lonza Group, and Merck hold significant market share due to their advanced technological offerings, global presence, and extensive customer bases. These companies benefit from strong R&D capabilities, strategic partnerships with hospitals, research institutions, and pharmaceutical companies, and a deep understanding of regulatory requirements. However, the market also features several smaller, specialized firms focusing on niche areas like gene editing, stem-cell processing, or specific automated solutions, contributing to its dynamic and evolving nature. The characteristics of this market are shaped by innovation, with companies continually enhancing their product portfolios to improve scalability, safety, and efficiency in cell therapy production. High regulatory barriers and the need for compliance with stringent health and safety standards influence market dynamics, requiring firms to invest heavily in research, quality assurance, and regulatory approvals. The market is also witnessing an increased focus on automation to drive down production costs and improve throughput, as well as the shift toward closed systems to ensure sterility and reduce contamination risks.

Report Coverage:

The research report offers an in-depth analysis based on product type, technology and end user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

  1. The automated and closed-cell therapy processing systems market is expected to continue its rapid expansion, driven by the growing demand for cell-based therapies and personalized medicine.
  2. Advancements in biomanufacturing technologies, such as automation and closed systems, will further enhance the efficiency and safety of cell therapy production.
  3. As the need for scalable, cost-effective manufacturing solutions increases, the market will likely see significant innovation in automated systems, improving production yields and reducing operational costs.
  4. Regulatory frameworks will continue to evolve, presenting both challenges and opportunities for companies to develop compliant, high-quality processing systems.
  5. With rising healthcare expenditures, particularly in emerging markets, there will be a growing demand for advanced biomanufacturing solutions to meet the needs of local populations.
  6. Research and development in cell therapies, especially for chronic diseases and cancer, will drive the adoption of more sophisticated processing systems.
  7. Partnerships between biotechnology companies and technology providers will become more prevalent as businesses look for integrated solutions to enhance efficiency.
  8. North America and Europe will remain key markets, but the Asia-Pacific region will witness accelerated growth due to expanding biopharmaceutical industries and government support.
  9. The continued trend toward personalized medicine will require flexible, adaptable systems to cater to diverse patient needs and treatment protocols.
  10. The increasing focus on minimizing contamination risks will solidify the role of closed system technologies in the global cell therapy market.
Automated & Closed-Cell Therapy Processing Systems Market Size and Share 2032
Report Attribute Details
Details
Historical Period
-
Base Year
2024
Forecast Period
2024–2032
Automated and Closed Cell Therapy Processing Systems Size 2024
USD 1,201.39 million
Automated and Closed Cell Therapy Processing Systems CAGR
23%
Automated and Closed Cell Therapy Processing Systems Size 2032
USD 6,293.97 million

Request a Free Sample

Fill in your details and we'll send you a free sample report.

  • Sample data tables & charts
  • Research methodology

Market Dynamics

Advancements in Cell-Based Therapies

Continuous innovation in cell and gene therapies is increasing the need for efficient, scalable, and safe manufacturing systems, driving adoption of automated and closed processing solutions to meet clinical and commercial demand.

Personalized Medicine Expansion

The shift toward personalized medicine requires flexible, contamination-free, and reproducible cell therapy manufacturing, making automated and closed systems essential for producing individualized treatments at scale.

Regulatory and Government Support

Supportive regulatory frameworks and significant government funding for cell therapy R&D, especially in North America and Europe, are accelerating the adoption of advanced processing systems by providing clarity and incentives for manufacturers.

Rising Prevalence of Chronic Diseases and Aging Populations

The global increase in chronic and age-related diseases is boosting demand for cell therapies, necessitating robust, automated systems capable of producing high-quality therapies efficiently and safely.

Need for Contamination Control and Manufacturing Efficiency

Closed system technologies are increasingly adopted to minimize contamination risks and ensure regulatory compliance, while automation reduces human error and increases throughput, both critical for the sensitive nature of cell therapy products.

Need a Custom Version of This Report?

Tailor the scope, geography, or segments to your exact requirements.

  • Custom geography or segment scope
  • Direct access to our analyst team

Frequently Asked Questions

What is the projected growth of the Automated and Closed Cell Therapy Processing Systems Market?
The market is projected to grow from USD 1,201.39 million in 2024 to USD 6,293.97 million by 2032, with a compound annual growth rate (CAGR) of 23% from 2024 to 2032.
What are the key drivers of growth in the market?
Key drivers include advancements in cell-based therapies, increasing demand for personalized medicine, greater adoption of automation in manufacturing, and the growing need for scalable and efficient production solutions. The rise in clinical trials and chronic diseases also plays a major role.
Why is the shift toward closed systems important in cell therapy production?
Closed systems are crucial for ensuring higher safety levels and minimizing contamination risks during the production of sensitive biological products, which is vital for maintaining the integrity of cell therapies.
Which region is leading the market for automated and closed cell therapy processing systems?
North America leads the market, driven by advanced healthcare infrastructure, strong R&D focus, and significant investments in the biotechnology and pharmaceutical sectors.
What is the market outlook for Asia Pacific?
Asia Pacific, including countries like China, Japan, and India, is expected to experience substantial growth due to increasing healthcare expenditures, expanding infrastructure, and a growing biopharmaceutical sector.
Who are the major players in the global automated and closed cell therapy processing systems market?
The top players include Lonza, Miltenyi Biotec, Cytiva (Danaher Corp.), Fresenius Kabi, Terumo Corp., BioSpherix Ltd, ThermoGenesis Holdings Inc, Sartorius AG, Thermo Fisher Scientific Inc, Cellares Inc, and Others.

Table of Content

Chapter 1 Market Segmentation

  • 1.1 Segmentation Framework
    • 1.1.1 Product and Service Classification
    • 1.1.2 Application and End-Use Classification
    • 1.1.3 Technology and Solution Classification
    • 1.1.4 Customer and Distribution Channel Classification
    • 1.1.5 Geographic Segmentation
    • 1.1.6 Market Segment Definitions and Boundaries
  • 1.2 By End-User
    • 1.2.1 Hospitals
    • 1.2.2 Research Institutions
    • 1.2.3 Biotechnology Companies
    • 1.2.4 Pharmaceutical Companies
  • 1.3 By Technology
    • 1.3.1 Automation Technology
    • 1.3.2 Gene-Editing Technology
    • 1.3.3 Stem-Cell Processing Technology
  • 1.4 By Product Type
    • 1.4.1 Automated Cell Therapy Processing Systems
    • 1.4.2 Closed Cell Therapy Processing Systems

Chapter 2 Introduction

  • 2.1 Report Objectives and Scope
  • 2.2 Product Definition and Industry Terminology
  • 2.3 Market Inclusions and Exclusions
  • 2.4 Research Process
    • 2.4.1 Primary Research and Expert Interviews
    • 2.4.2 Secondary Research and Source Review
    • 2.4.3 Top-Down and Bottom-Up Estimation
    • 2.4.4 Data Triangulation and Verification
  • 2.5 Market Size Measurement Basis
    • 2.5.1 2024: USD 1,201.39 million → 2032: USD 6,293.97 million
  • 2.6 Historical and Forecast Reference Periods
    • 2.6.1 Base Year: 2024
    • 2.6.2 Forecast Period: 2024-2032
  • 2.7 Research Assumptions and Limitations

Chapter 3 Executive Summary

  • 3.1 Market Snapshot and Key Findings
  • 3.2 Base-Year Market Size, 2024
  • 3.3 Forecast Market Size, 2032
  • 3.4 Revenue and Volume Growth Outlook
  • 3.5 Key Demand and Supply Indicators
  • 3.6 Leading Market Segments
  • 3.7 Fastest-Growing Market Opportunities
  • 3.8 Regional Performance Highlights
  • 3.9 Technology and Industry Transformation
  • 3.10 Competitive Landscape Summary
  • 3.11 Analyst View and Strategic Implications

Chapter 4 Global Automated and Closed Cell Therapy Processing Systems Market Trends and Developments

  • 4.1 Historical Industry Development
  • 4.2 Recent Market Trends and Developments
  • 4.3 Demand and Customer Behavior Trends
  • 4.4 Technology and Product Innovation
  • 4.5 Artificial Intelligence, Automation and Digitalization
  • 4.6 Local Manufacturing and Supply Chain Realignment
  • 4.7 Industry Partnerships, Mergers and Acquisitions
  • 4.8 Sustainability and Circular Economy Developments
  • 4.9 Government and Private Sector Investment Trends
  • 4.10 Emerging Business Models and Commercialization
  • 4.11 Industry Developments and Announcements

Chapter 5 Global Automated and Closed Cell Therapy Processing Systems Market Production, Supply and Demand Analysis

  • 5.1 Demand Trend and Consumption Analysis
  • 5.2 Demand Forecast, 2024-2032
  • 5.3 Production and Output Trend
  • 5.4 Production and Output Forecast, 2024-2032
  • 5.5 Installed Capacity and Capacity Utilization
  • 5.6 Company-Wise Production Plants and Statistics
    • 5.6.1 Installed Production Capacity
    • 5.6.2 Actual Production
    • 5.6.3 Planned Capacity and Expansion Targets
  • 5.7 Supply Chain Structure and Procurement Trends
  • 5.8 Supply-Demand Gap and Bottlenecks
  • 5.9 Import Dependence and Sourcing Structure
  • 5.10 Contract Manufacturing and Outsourcing
  • 5.11 Regional Supply and Demand Concentration

Chapter 6 Global Automated and Closed Cell Therapy Processing Systems Market Pricing Analysis

  • 6.1 Pricing Structure and Measurement
  • 6.2 Historical Pricing Trends
  • 6.3 Pricing Outlook, 2024-2032
  • 6.4 Average Selling Price and Unit Economics
  • 6.5 Pricing by Product and Market Segment
  • 6.6 Geographic Pricing Differences
  • 6.7 Key Input, Energy, Labor and Logistics Costs
  • 6.8 Contract Pricing and Purchasing Models
  • 6.9 Pricing Sensitivity and Competitive Positioning
  • 6.10 Price, Margin and Profitability Implications

Chapter 7 Global Automated and Closed Cell Therapy Processing Systems Market Dynamics

  • 7.1 Market Growth Drivers
    • 7.1.1 Demand-Side Drivers
    • 7.1.2 Technology and Innovation Drivers
    • 7.1.3 Infrastructure and Investment Drivers
    • 7.1.4 Regulatory and Policy Drivers
  • 7.2 Market Restraints
    • 7.2.1 Cost and Affordability Constraints
    • 7.2.2 Technology and Adoption Barriers
    • 7.2.3 Supply Chain and Operational Constraints
  • 7.3 Market Challenges
    • 7.3.1 Competitive Pressure and Margin Erosion
    • 7.3.2 Skills, Infrastructure and Implementation Gaps
  • 7.4 Emerging Market Opportunities
  • 7.5 Market Dynamics Impact and Time-Horizon Assessment

Chapter 8 Global Automated and Closed Cell Therapy Processing Systems Value Chain Analysis

  • 8.1 Industry Value Chain Overview
  • 8.2 Upstream Suppliers and Critical Inputs
  • 8.3 Technology and Component Providers
  • 8.4 Manufacturing or Service Delivery
  • 8.5 Distribution, Channel Partners and Integrators
  • 8.6 Downstream Applications and End Users
  • 8.7 Value Addition and Profit Pools
  • 8.8 Vertical Integration and Outsourcing
  • 8.9 Supplier Concentration and Risk
  • 8.10 Supply Chain Localization and Resilience

Chapter 9 Global Automated and Closed Cell Therapy Processing Systems Market Regulations and Policies

  • 9.1 Relevant Laws, Standards and Compliance Frameworks
  • 9.2 Product, Service, Safety and Quality Requirements
  • 9.3 Government Policies, Incentives and Subsidies
  • 9.4 Imports, Exports and Trade Barriers
  • 9.5 Public Procurement and Local Content Requirements
  • 9.6 Environmental and Sustainability Compliance
  • 9.7 Upcoming Policy Changes and Market Implications

Chapter 10 Global Automated and Closed Cell Therapy Processing Systems Market Hotspots and Opportunities

  • 10.1 Market Opportunity Mapping and Growth Hotspots
  • 10.2 High-Growth Applications and Customer Groups
  • 10.3 Underserved Markets and White-Space Opportunities
  • 10.4 Emerging Technology and Product Opportunities
  • 10.5 New Capacity and Investment Hotspots
  • 10.6 Market Entry and Expansion Opportunities
  • 10.7 Distribution and Partnership Opportunities
  • 10.8 Near-Term and Long-Term Commercial Potential
  • 10.9 Opportunity Attractiveness and Execution Risks

Chapter 11 Global Automated and Closed Cell Therapy Processing Systems Market Outlook, 2024-2032

  • 11.1 Market Size and Analysis
    • 11.1.1 Revenue (Market Measurement: 2024: USD 1,201.39 million → 2032: USD 6,293.97 million)
    • 11.1.2 Market Volume and Quantity Sold
    • 11.1.3 Historical Market Size
    • 11.1.4 Base-Year Market Size, 2024
  • 11.2 Market Forecast, 2024-2032
    • 11.2.1 Revenue Forecast to 2032
    • 11.2.2 Volume Forecast to 2032
    • 11.2.3 CAGR and Year-on-Year Growth
    • 11.2.4 Incremental Revenue Opportunity
  • 11.3 Forecast Assumptions and Scenario Analysis
    • 11.3.1 Base-Case Forecast
    • 11.3.2 Optimistic and Conservative Scenarios
    • 11.3.3 Technology, Pricing and Policy Sensitivities
  • 11.4 Market Attractiveness and Growth Outlook

Chapter 12 Global Automated and Closed Cell Therapy Processing Systems Market Segmentation and Outlook

  • 12.1 Segmentation Summary and Market Shares, 2024
  • 12.2 Largest and Fastest-Growing Segments
  • 12.3 By End-User - Market Size and Forecast, 2024-2032
    • 12.3.1 Segment Definition and Scope
    • 12.3.2 Historical Market Size
    • 12.3.3 Revenue Forecast, 2024-2032
    • 12.3.4 Volume Forecast, 2024-2032
    • 12.3.5 Base-Year Market Share, 2024
    • 12.3.6 Segment CAGR and Growth Drivers
    • 12.3.7 Subsegment Market Size and Forecast
      • 12.3.7.1 Hospitals
      • 12.3.7.2 Research Institutions
      • 12.3.7.3 Biotechnology Companies
      • 12.3.7.4 Pharmaceutical Companies
    • 12.3.8 Subsegment Pricing and Adoption Trends
    • 12.3.9 Leading Suppliers and Competition
    • 12.3.10 Regional Demand and Opportunities
  • 12.4 By Technology - Market Size and Forecast, 2024-2032
    • 12.4.1 Segment Definition and Scope
    • 12.4.2 Historical Market Size
    • 12.4.3 Revenue Forecast, 2024-2032
    • 12.4.4 Volume Forecast, 2024-2032
    • 12.4.5 Base-Year Market Share, 2024
    • 12.4.6 Segment CAGR and Growth Drivers
    • 12.4.7 Subsegment Market Size and Forecast
      • 12.4.7.1 Automation Technology
      • 12.4.7.2 Gene-Editing Technology
      • 12.4.7.3 Stem-Cell Processing Technology
    • 12.4.8 Subsegment Pricing and Adoption Trends
    • 12.4.9 Leading Suppliers and Competition
    • 12.4.10 Regional Demand and Opportunities
  • 12.5 By Product Type - Market Size and Forecast, 2024-2032
    • 12.5.1 Segment Definition and Scope
    • 12.5.2 Historical Market Size
    • 12.5.3 Revenue Forecast, 2024-2032
    • 12.5.4 Volume Forecast, 2024-2032
    • 12.5.5 Base-Year Market Share, 2024
    • 12.5.6 Segment CAGR and Growth Drivers
    • 12.5.7 Subsegment Market Size and Forecast
      • 12.5.7.1 Automated Cell Therapy Processing Systems
      • 12.5.7.2 Closed Cell Therapy Processing Systems
    • 12.5.8 Subsegment Pricing and Adoption Trends
    • 12.5.9 Leading Suppliers and Competition
    • 12.5.10 Regional Demand and Opportunities
  • 12.6 Segment Growth Comparison
  • 12.7 Segment Attractiveness and Priority Matrix

Chapter 13 Global Automated and Closed Cell Therapy Processing Systems End-Use and Application Market Outlook

  • 13.1 End-Use Industry and Customer Demand Structure
  • 13.2 Leading Applications and Customer Groups
  • 13.3 End-Use Market Size, Share and Forecast
  • 13.4 Major End-Use Industry Deep Dives
    • 13.4.1 Customer Requirements and Use Cases
    • 13.4.2 Demand and Replacement Cycles
    • 13.4.3 Technical and Regulatory Considerations
    • 13.4.4 Purchasing and Procurement Models
    • 13.4.5 Leading Vendors and Distribution Channels
    • 13.4.6 Forecast and Commercial Opportunities
  • 13.5 Emerging Applications and Cross-Segment Demand
  • 13.6 End-Use Industry Investment Priorities

Chapter 14 Global Automated and Closed Cell Therapy Processing Systems Geographic Market Outlook, 2024-2032

  • 14.1 Regional Market Size and Share, 2024
  • 14.2 Regional Market Forecast, 2024-2032
  • 14.3 Regional Pricing, Production and Demand Differences
  • 14.4 North America
    • 14.4.1 United States
    • 14.4.2 Canada
    • 14.4.3 Mexico
  • 14.5 Europe
    • 14.5.1 Germany
    • 14.5.2 France
    • 14.5.3 Italy
    • 14.5.4 United Kingdom
    • 14.5.5 Spain
    • 14.5.6 Poland
    • 14.5.7 Russia
    • 14.5.8 Netherlands
    • 14.5.9 Belgium
    • 14.5.10 Sweden
    • 14.5.11 Denmark
    • 14.5.12 Norway
    • 14.5.13 Rest of Europe
  • 14.6 Asia Pacific
    • 14.6.1 China
    • 14.6.2 India
    • 14.6.3 Japan
    • 14.6.4 South Korea
    • 14.6.5 Thailand
    • 14.6.6 Indonesia
    • 14.6.7 Vietnam
    • 14.6.8 Malaysia
    • 14.6.9 Australia
    • 14.6.10 Rest of Asia Pacific
  • 14.7 Latin America
    • 14.7.1 Brazil
    • 14.7.2 Argentina
    • 14.7.3 Colombia
    • 14.7.4 Chile
    • 14.7.5 Rest of Latin America
  • 14.8 Middle East
    • 14.8.1 Saudi Arabia
    • 14.8.2 United Arab Emirates
    • 14.8.3 Turkey
    • 14.8.4 Israel
    • 14.8.5 Iran
    • 14.8.6 Rest of the Middle East
  • 14.9 Africa
    • 14.9.1 South Africa
    • 14.9.2 Egypt
    • 14.9.3 Nigeria
    • 14.9.4 Morocco
    • 14.9.5 Rest of Africa
  • 14.10 Regional Investment, Policy and Supply Chain Differences
  • 14.11 Regional Competitive Landscape
  • 14.12 Geographic Growth Hotspots

Chapter 15 Global Automated and Closed Cell Therapy Processing Systems Technology, Innovation and Sustainability Outlook

  • 15.1 Technology Landscape and Maturity
  • 15.2 Product, Process and Service Innovation
  • 15.3 AI, Automation and Digital Tools in the Industry
  • 15.4 Technology Adoption and Performance Benchmarking
  • 15.5 Innovation Pipeline and R&D Investment
  • 15.6 Patent and Intellectual Property Trends
  • 15.7 Energy Efficiency and Resource Management
  • 15.8 Sustainability, Recycling and Circularity
  • 15.9 Technology Roadmap, 2024-2032
  • 15.10 Risks of Obsolescence and Technology Substitution

Chapter 16 Global Automated and Closed Cell Therapy Processing Systems Market Key Strategic Imperatives

  • 16.1 Growth and Market Entry Priorities
  • 16.2 High-Return Products and Segments
  • 16.3 Pricing, Profitability and Cost Optimization
  • 16.4 Technology Investment and Product Differentiation
  • 16.5 Supply Chain Localization and Resilience
  • 16.6 Distribution and Customer Acquisition
  • 16.7 Partnership, Acquisition and Capacity Strategy
  • 16.8 Regional Expansion Priorities
  • 16.9 Short-, Medium- and Long-Term Actions

Chapter 17 Competition Outlook

  • 17.1 Industry Competition Characteristics
  • 17.2 Market Structure and Concentration
  • 17.3 Market Share and Competitive Positioning, 2024
  • 17.4 Company-Wise Revenue and Product Benchmarking
  • 17.5 Production and Service Capacity Benchmarking
  • 17.6 Technology, Pricing and Differentiation
  • 17.7 Regional Footprint and Distribution Strength
  • 17.8 Mergers, Acquisitions and Strategic Alliances
  • 17.9 New Entrants and Competitive Threats
  • 17.10 Porter's Five Forces and Industry Attractiveness
  • 17.11 Competitive Outlook, 2024-2032

Chapter 18 Company Profiles

  • 18.1 Company Coverage and Selection Criteria
  • 18.2 Miltenyi Biotec
    • 18.2.1 Business Description
    • 18.2.2 Company Ownership and Geographic Presence
    • 18.2.3 Product and Service Portfolio
    • 18.2.4 Manufacturing and Operating Footprint
    • 18.2.5 Production Capacity and Expansion Plans
    • 18.2.6 Financial Performance and Investment
    • 18.2.7 Market Share and Competitive Position
    • 18.2.8 Technology and Innovation Capabilities
    • 18.2.9 Strategic Alliances or Partnerships
    • 18.2.10 Recent Developments
    • 18.2.11 Growth Strategy and Outlook
  • 18.3 Lonza
  • 18.4 Fresenius Kabi AG
  • 18.5 Danaher Corporation
  • 18.6 BioSpherix, LLC
  • 18.7 Terumo Corporation
  • 18.8 Sartorius AG
  • 18.9 ThermoGenesis Holdings, Inc.
  • 18.10 CELLARS
  • 18.11 Thermo Fisher Scientific Inc.
  • 18.12 Other Relevant Market Participants

Note: Every listed company is profiled on the structure shown under the first company. The company list is preliminary and may change based on research findings, market developments, data availability and client requirements.

Chapter 19 Disclaimer

  • 19.1 Research and Forecast Disclaimer
  • 19.2 Data Source and Estimation Limitations

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.

Methodology

Meet the Team

Shweta Bisht
Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

Deepti Agrawal

Reviewed by

Deepti Agrawal

Head of Editorial Operations

Related Topics

Medical Gases Market Size, Share, Growth and Forecast, 2025-2035

Medical gases market worth USD 17.09 billion in 2025 is set to reach USD 31.77 billion by 2035 at a 6.40% CAGR as hospital and home oxygen use grows.

Acetaminophen Market Size, Share, Growth and Forecast, 2025-2035

Acetaminophen market worth USD 10.01 billion in 2025 is set to reach USD 15.29 billion by 2035 at a 4.33% CAGR as fever and joint pain demand grows.

Urinary Tract Infection Treatment Market Size, Share, Growth and Forecast, 2025-2035

UTI treatment market worth USD 10.18 billion in 2025 is set to reach USD 14.85 billion by 2035 at a 3.85% CAGR as resistance shifts care to newer drugs.

Dental Handpiece Market Size, Share, Growth and Forecast, 2025-2035

Dental handpiece market worth USD 2.07 billion in 2025 reaches USD 3.65 billion by 2035, at a 5.80% CAGR as electric and surgical systems gain share.

Pharmaceutical Logistics Market Size, Share, Growth and Forecast, 2025-2035

Pharmaceutical logistics market worth USD 108.00 billion in 2025 is set to reach USD 240.83 billion by 2035, rising at an 8.35% CAGR on biologics and trade.

North America Retail Pharmacy Market Size, Share, Growth and Forecast, 2025-2035

North America retail pharmacy market worth USD 562.72 billion in 2025 is set to reach USD 821.03 billion by 2035 at a 3.85% CAGR as prescriptions rise